文献速递鼻科

口服糖皮质激素应否用于慢性鼻窦炎的药物治疗?一项风险分析

Should Oral Corticosteroids be Used in Medical Therapy for Chronic Rhinosinusitis? A Risk Analysis.
PubMed 文献 · Laryngoscope · 2020-07-07

本研究通过基于概率的风险决策分析,比较口服糖皮质激素(OCS)与内镜鼻窦手术(ESS)的风险,计算避免进一步干预所需的最低有效性(MERAFI)。结果显示,慢性鼻窦炎不伴鼻息肉(CRSsNP)的MERAFI为20.8%(95% CI 20.7-20.9%),伴鼻息肉(CRSwNP)为16.8%(95% CI 16.7-16.9%)。鉴于文献报告OCS有效性在CRSsNP为34-71%、CRSwNP为46-63%,将OCS纳入适当药物治疗可能是较低风险策略。

要点

  • OCS避免ESS所需的最低有效性:CRSsNP为20.8%,CRSwNP为16.8%。
  • 文献报告OCS有效性范围:CRSsNP 34-71%,CRSwNP 46-63%。
  • 基于上述阈值,OCS纳入适当药物治疗可能是较低风险策略。

核心结论

  • 鉴于报告的有效性高于MERAFI阈值,将OCS纳入适当药物治疗可能是较低风险策略。

研究设计与样本

  • 基于文献报告的OCS和ESS不良事件发生率及影响,构建概率风险决策分析,并进行蒙特卡洛分析。

主要发现

  • CRSsNP的MERAFI为20.8%(95% CI 20.7-20.9%),CRSwNP的MERAFI为16.8%(95% CI 16.7-16.9%)。
  • 文献报告OCS有效性在CRSsNP为34-71%,在CRSwNP为46-63%。

关键数值与推荐

  • MERAFI:CRSsNP 20.8%(95% CI 20.7-20.9%),CRSwNP 16.8%(95% CI 16.7-16.9%)。
  • OCS报告有效性:CRSsNP 34-71%,CRSwNP 46-63%。

临床怎么用

  • 在缺乏标准化处方方案的情况下,可参考MERAFI阈值评估OCS用于适当药物治疗的风险获益。

局限性

  • 分析基于文献报告的 incidence 和影响,而非标准化处方方案下的直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Oral corticosteroid (OCS) as a part of appropriate medical therapy (AMT) (formerly maximal medical therapy) in chronic rhinosinusitis remains controversial. While the risks of OCS are well known, the benefit remains unclear due the absence of a standardized prescribing regimen. Consequently, it is difficult to characterize whether the risks of OCS and its ability to avert endoscopic sinus surgery (ESS) are helpful in AMT. When OCS is highly effective at averting surgery, the lesser risks of OCS would be justified because it can avoid the greater risks of ESS. When OCS is poorly effective at averting ESS, the risks of OCS would not be justified because many patients will be exposed to both risks. This study seeks to identify the threshold effectiveness of OCS at averting ESS that would minimize risk exposure to patients. METHODS: A probabilistic risks-based decision analysis was constructed from literature reported incidences and impacts of adverse events of OCS and ESS. Monte Carlo analysis was performed to identify the minimum effectiveness required to avoid further intervention (MERAFI) for chronic sinusitis without nasal polyp (CRSsNP) and chronic sinusitis with nasal polyp (CRSwNP). RESULTS: The analysis showed MERAFI results of 20.8% (95% CI 20.7-20.9%) for CRSsNP and 16.8% (95% CI 16.7-16.9%) for CRSwNP. CONCLUSIONS: Given reported OCS effectiveness in the range of 34-71% in CRSsNP and 46-63% in CRSwNP, this analysis suggests that the inclusion of OCS in AMT may be the lower risk strategy. LEVEL OF EVIDENCE: N/A Laryngoscope, 131:473-481, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Leung RM, Smith TL, Kern RC, et al. Should Oral Corticosteroids be Used in Medical Therapy for Chronic Rhinosinusitis? A Risk Analysis. Laryngoscope. 2020. PMID: 32633822. doi:10.1002/lary.28843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。